These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 11104831

  • 1. Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
    Assié MB, Koek W.
    Eur J Pharmacol; 2000 Dec 08; 409(2):173-7. PubMed ID: 11104831
    [Abstract] [Full Text] [Related]

  • 2. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
    Trillat AC, Malagié I, Mathé-Allainmat M, Anmela MC, Jacquot C, Langlois M, Gardier AM.
    Eur J Pharmacol; 1998 Apr 17; 347(1):41-9. PubMed ID: 9650846
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS, Assié MB, Koek W.
    J Pharmacol Exp Ther; 1997 Aug 17; 282(2):747-59. PubMed ID: 9262338
    [Abstract] [Full Text] [Related]

  • 4. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties.
    Assié MB, Koek W.
    Eur J Pharmacol; 1996 May 23; 304(1-3):15-21. PubMed ID: 8813579
    [Abstract] [Full Text] [Related]

  • 5. Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors.
    Bosker FJ, de Winter TY, Klompmakers AA, Westenberg HG.
    J Neurochem; 1996 Jun 23; 66(6):2546-55. PubMed ID: 8632181
    [Abstract] [Full Text] [Related]

  • 6. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF, Lesourd M, Mocaer E, Koolhaas JM.
    J Pharmacol Exp Ther; 1999 Mar 23; 288(3):1125-33. PubMed ID: 10027850
    [Abstract] [Full Text] [Related]

  • 7. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.
    Eur J Pharmacol; 2005 Mar 07; 510(1-2):49-57. PubMed ID: 15740724
    [Abstract] [Full Text] [Related]

  • 8. Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis.
    Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K.
    Neurosci Res; 1998 May 07; 31(1):23-9. PubMed ID: 9704975
    [Abstract] [Full Text] [Related]

  • 9. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
    Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ.
    Psychopharmacology (Berl); 2000 Sep 07; 152(1):55-66. PubMed ID: 11041316
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of 5-HT agonists and antagonists on the repeated acquisition and performance of response sequences in monkeys.
    Winsauer PJ, Moerschbaecher JM.
    Behav Pharmacol; 2000 Nov 07; 11(7-8):535-53. PubMed ID: 11198126
    [Abstract] [Full Text] [Related]

  • 11. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist.
    Caicoya AG, Beneytez ME, Delgado M, Manzanares J, López-Rodríguez ML, Benhamu B, Morcillo MJ, Pozo MA, Rubia FJ, Fuentes JA.
    Pharmacology; 2001 May 07; 62(4):234-42. PubMed ID: 11360001
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain.
    Casanovas JM, Vilaró MT, Mengod G, Artigas F.
    J Neurochem; 1999 Jan 07; 72(1):262-72. PubMed ID: 9886078
    [Abstract] [Full Text] [Related]

  • 17. Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study.
    Routledge C, Gurling J, Wright IK, Dourish CT.
    Eur J Pharmacol; 1993 Aug 03; 239(1-3):195-202. PubMed ID: 8223894
    [Abstract] [Full Text] [Related]

  • 18. 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors.
    Hajós-Korcsok E, Sharp T.
    Eur J Pharmacol; 1996 Oct 31; 314(3):285-91. PubMed ID: 8957248
    [Abstract] [Full Text] [Related]

  • 19. Activation of 5-HT(1A) autoreceptors enhances the inhibitory effect of galanin on hippocampal 5-HT release in vivo.
    Yoshitake T, Yoshitake S, Yamaguchi M, Ogren SO, Kehr J.
    Neuropharmacology; 2003 Feb 31; 44(2):206-13. PubMed ID: 12623219
    [Abstract] [Full Text] [Related]

  • 20. S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
    Newman-Tancredi A, Chaput C, Verrièle L, Millan MJ.
    Eur J Pharmacol; 1996 Jun 20; 307(1):107-11. PubMed ID: 8831111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.